|
| TARGETS
FOR DRUG DISCOVERY |
Protein-Protein Interactions as Small Molecule Drug Targets:
What Has Been Learned?
David C. Fry, Ph.D., Senior Research Leader, Roche Research Center,
Hoffmann-La Roche, Inc.
A Taxonomy Approach
John Van Drie, Ph.D, Director, Computer-Aided Drug Discovery, Novartis
Institutes for Biomedical Research
Inhibition of TGF-Beta Family Signaling by Follistatin:
Potential Therapeutic Indications
Marko Hyvonen, Ph.D., Research Fellow and Coordinator, Department of
Biochemistry and Fragment-Based Drug Discovery Program, University of Cambridge |
| TECHNOLOGIES
FOR TACKLING |
FEATURED PRESENTATION
Computational Design and Analysis of Promiscuous and
Highly Specific Protein Interfaces
Tanja Kortemme, Ph.D., Assistant Professor, Biopharmaceutical Sciences,
California Institute for Quantitative Biomedical Research, University of
California-San Francisco
Targeting Protein-Protein Interactions in the Beta-Catenin
and HSP20 Pathways
Sudhir R. Sahasrabudhe, Ph.D., Chief Scientific Officer, Prolexys
Pharmaceuticals Inc.
CDK2/CYCLIN A Recruitment Site Inhibitors: A Peptide
to Small Molecule Approach
Daniel Sutherlin, Ph.D., Scientist, Medicinal Chemistry, Genentech
Inc.
Cellular Consequences of Inhibiting Bcl2 / BH3
Protein-Protein Interactions: Tools to Evaluate Candidate Bcl-2
Antagonists
Christian Fritz, Ph.D., Senior Director of Cancer Biology, Cancer
Biology, Infinity Pharmaceuticals, Inc.
Fragment-Based Approaches to Disrupt Protein-Protein
Interactions by NMR
Chaohong Sun, Ph.D., Associate Research Investigator, Protein NMR
Research, Abbott
REPLACE: A Strategy for Iterative Design of Cyclin
Dependant Kinase Inhibitors
Campbell McInnes, Ph.D., Assistant Professor, Pharmaceutical
Sciences, University of South Carolina
| CASE
STUDIES AND APPLICATIONS |
A Novel Mechanism for Small Molecule Inhibition of
TNF-a.
Molly M. He, Ph.D., Senior Scientist, Protein Sciences, Sunesis
Pharmaceuticals Inc.
Inhibitors of Apoptosis Proteins: Application of
Structure Based Drug Design to the Taming of a Protein-Protein Interaction
Target.
Christopher S. Straub, Ph.D., Senior Scientist, Oncology Chemistry,
Novartis Institutes for Biomedical Research, Inc.
| Scientific Advisory
Board |
Don Emerson, Ph.D., Research Fellow, Protein NMR and
Biophysics Group, Pfizer Inc.
David C. Fry, Ph.D., Senior Research Leader, Roche Research Center, Hoffmann-La
Roche, Inc.
Marina Nelen, Ph.D., Senior Scientist, Lead Generation Biology, Johnson &
Johnson
PRD
John Van Drie, Ph.D., Director, Computer-Aided Drug Discovery, Novartis
Institutes for Biomedical Research |
|
|
|
